{"gene":"TIMP3","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2001,"finding":"The N-terminal inhibitory domain of TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5), with Ki values in the subnanomolar range, establishing TIMP-3 as the first endogenous regulator of aggrecanases.","method":"In vitro enzymatic inhibition assay with recombinant N-terminal TIMP-3 domain expressed from bacterial inclusion bodies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro kinetic inhibition assay with defined Ki values, rigorous biochemical characterization","pmids":["11278243"],"is_preprint":false},{"year":2000,"finding":"TIMP-3 (but not TIMP-2 or TIMP-4) inhibits ADAM-10 with an apparent inhibition constant of ~0.9 nM, and is the only TIMP able to inhibit both ADAM-10 and TACE (ADAM-17).","method":"Quenched fluorescent substrate assay and myelin basic protein degradation assay using recombinant ADAM-10 catalytic domain","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic inhibition with quantified Ki, multiple substrate assays","pmids":["10818225"],"is_preprint":false},{"year":2012,"finding":"Under basal conditions, TACE (ADAM17) exists predominantly as cell-surface dimers that associate efficiently with TIMP3 to suppress TACE activity; activation of ERK or p38 MAPK shifts the equilibrium toward TACE monomers, reducing TIMP3 association and increasing TACE-mediated proteolysis.","method":"Cell-surface dimerization assays, co-immunoprecipitation of TACE with TIMP3, MAPK pathway manipulation, TGF-α shedding readout","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, multiple pathway manipulations, defined mechanistic model with functional readout","pmids":["22550340"],"is_preprint":false},{"year":2005,"finding":"TIMP3 deficiency leads to unchecked TACE activity, increased soluble TNF-α, and promotes diabetes and vascular inflammation; pharmacological TACE inhibition reverses these phenotypes, placing TIMP3 upstream of TACE/TNF-α signaling in metabolic disease.","method":"Genetic epistasis in Insr+/- and Insr+/-Timp3+/- double heterozygous mice; TACE activity assays; pharmacological TACE inhibition rescue experiments","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with double mutant mice, pharmacological rescue, TACE activity measurements","pmids":["16294222"],"is_preprint":false},{"year":2004,"finding":"TIMP-3 deficiency in mice triggers spontaneous dilated cardiomyopathy with elevated MMP-9 activity and TNF-α activation, demonstrating that TIMP-3 is required to maintain myocardial matrix homeostasis and suppress proinflammatory remodeling.","method":"Targeted Timp3-knockout mice evaluated longitudinally; gelatinase bioassay for MMP activity; echocardiographic and histological analysis","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — clean KO model with defined phenotypic readout, MMP activity assays, replicated across aging time points","pmids":["15262835"],"is_preprint":false},{"year":2009,"finding":"TIMP3 deficiency accelerates renal tubulointerstitial fibrosis after ureteral obstruction via elevated TACE activity, increased soluble TNF-α, and enhanced MMP-2 activation; additional deletion of TNF-α markedly reduces inflammation and fibrosis, placing TIMP3 upstream of TACE/TNF-α and MMP axes in kidney injury.","method":"TIMP3-/- mice and TIMP3-/-/TNFα-/- double-KO mice with unilateral ureteral obstruction; TACE activity assays; gelatin zymography; MMP inhibitor treatment","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 — genetic double-KO epistasis, pharmacological inhibition, multiple enzymatic assays","pmids":["19406980"],"is_preprint":false},{"year":2007,"finding":"TIMP-3 inhibits ADAM-10 and ADAM-17-mediated alpha-secretase cleavage of APP and ApoER2, decreases their surface levels, and thereby increases beta-secretase cleavage and Aβ production; TIMP-3 protein levels are elevated in Alzheimer's disease brain.","method":"Cell-based alpha-secretase/beta-secretase cleavage assays in neuroblastoma and COS7 cells; surface protein measurement; Aβ ELISA; brain tissue immunoblot","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 — cell-based functional assays with multiple readouts, in vivo confirmation in transgenic mice and human AD tissue","pmids":["17913923"],"is_preprint":false},{"year":2015,"finding":"TIMP3 induces apoptosis in endothelial cells expressing VEGFR2 (KDR) through a caspase-independent mechanism involving inhibition of FAK tyrosine phosphorylation and disruption of β3 integrin/FAK/paxillin incorporation into focal adhesion contacts.","method":"Apoptosis assays in PAE/KDR vs PAE/β-R cells; caspase inhibitor experiments; FAK phosphorylation immunoblot; focal adhesion complex co-immunoprecipitation","journal":"Apoptosis : an international journal on programmed cell death","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional readouts and mechanistic pathway dissection, single lab","pmids":["25558000"],"is_preprint":false},{"year":2016,"finding":"TIMP3 acts through inhibition of the metalloprotease ADAM17 and its substrate HB-EGF to regulate cerebral arterial tone; in CADASIL mice with elevated TIMP3, exogenous ADAM17 or HB-EGF restores cerebral blood flow responses, and upregulated voltage-dependent potassium (KV) channel number in arterial myocytes is identified as a downstream effector.","method":"CADASIL mouse model; pharmacological and genetic manipulation of ADAM17/HB-EGF; cerebral blood flow measurements; patch-clamp electrophysiology of cerebral arterial myocytes","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological epistasis, electrophysiology, multiple orthogonal methods in vivo and ex vivo","pmids":["27476853"],"is_preprint":false},{"year":2016,"finding":"Elevated TIMP3 in CADASIL mice impairs functional hyperemia and cerebrovascular reactivity; haploinsufficiency of Timp3 rescues these CBF deficits downstream of Notch3ECD deposition, demonstrating TIMP3 accumulation as a causal contributor to cerebrovascular dysfunction.","method":"TgNotch3R169C mice crossed with Timp3 haploinsufficient mice; CBF measurements; myogenic tone assays; TgBAC-TIMP3 overexpression mouse","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 — genetic rescue in preclinical model, multiple functional vascular assays, TIMP3 overexpression model confirms phenotype","pmids":["26648042"],"is_preprint":false},{"year":2012,"finding":"Pericyte-derived TIMP3 stabilizes capillary tube networks and inhibits ADAMTS1-mediated metalloprotease activity in endothelial cells; Timp3-/- mice show spontaneous microvascular rarefaction and exaggerated fibrosis after kidney injury.","method":"3D capillary tube network assays with pericytes vs myofibroblasts; Timp3-/- mouse renal injury model; ADAMTS1/TIMP3 expression profiling","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 — in vitro reconstitution of vascular stabilization, KO mouse with defined phenotype, functional metalloprotease measurements","pmids":["22383695"],"is_preprint":false},{"year":2018,"finding":"Pericyte ALK5 (TGF-β receptor) signaling upregulates TIMP3 expression; ALK5-deficient brain pericytes downregulate TIMP3, causing enhanced perivascular MMP activity, endothelial hyperproliferation, and germinal matrix hemorrhage; exogenous TIMP3 administration rescues endothelial morphogenesis.","method":"Conditional pericyte Alk5 knockout mice; immunofluorescence; gelatin zymography; TIMP3 rescue administration in vivo","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined cellular phenotype, pharmacological rescue with TIMP3 protein, multiple orthogonal assays","pmids":["29456135"],"is_preprint":false},{"year":2008,"finding":"The N-terminal domains of TIMP-1 and TIMP-3 alone are insufficient to inhibit ADAM10; full-length TIMP-3 is required, indicating that regions beyond the N-terminal inhibitory domain contribute to ADAM10 inhibition, unlike the mechanism for MMP and ADAM17 inhibition.","method":"In vitro inhibition assays comparing N-terminal domain fragments vs full-length TIMP-1 and TIMP-3 against ADAM10, ADAM17, and MMPs","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro inhibition assays with defined domain constructs","pmids":["18215140"],"is_preprint":false},{"year":1997,"finding":"TIMP-3 protein is uniquely deposited in the extracellular matrix of Bruch's membrane in the retina/choroid and is not secreted into culture medium, unlike TIMP-1 and TIMP-2, explaining why TIMP-3 mutations cause retinal-specific pathology (Sorsby's fundus dystrophy).","method":"RT-PCR, Northern analysis, Western immunoblot, immunohistochemistry of human retina/choroid and cultured RPE cells and pericytes","journal":"Current eye research","confidence":"High","confidence_rationale":"Tier 2 — direct subcellular/extracellular localization by multiple orthogonal methods with functional implication","pmids":["9068940"],"is_preprint":false},{"year":2013,"finding":"Loss of TIMP3 in diabetic mice causes increased ADAM17 activity and elevated STAT1, which represses FoxO1 transcription; re-expression of TIMP3 in Timp3-/- mesangial cells rescues FoxO1 and its autophagy targets while decreasing STAT1, establishing a TIMP3→ADAM17→STAT1→FoxO1 pathway in diabetic nephropathy.","method":"Diabetic Timp3-/- mice; microarray; re-expression experiments in mesangial cells; STAT1 siRNA rescue; kidney biopsies from diabetic patients","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic KO mouse, cell-based rescue, siRNA epistasis, human tissue validation","pmids":["23401241"],"is_preprint":false},{"year":2016,"finding":"TIMP3 inhibits TIMP3 internalization via LRP-1 interaction; TIMP3 extracellular levels are regulated by endocytosis through LRP-1 cluster II; a soluble minireceptor (T3TRAP) that blocks TIMP3 binding to LRP-1 selectively increases extracellular TIMP3 and inhibits ADAM10-mediated shedding of multiple cell-surface proteins.","method":"Soluble LRP-1 minireceptor binding assays, biochemical TIMP-3/LRP-1 interaction assays, mass spectrometry-based secretome analysis","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"High","confidence_rationale":"Tier 1 — biochemical binding assays with defined domain mapping, MS secretome validation, multiple methods","pmids":["27476612"],"is_preprint":false},{"year":2018,"finding":"Increased TIMP-3 expression inhibits ADAM10-mediated shedding of multiple cell-surface proteins and simultaneously increases extracellular levels of soluble proteins (TIMP-1, MIF, SPARC) by competing with them for LRP-1-mediated endocytosis.","method":"Unbiased mass spectrometry secretome analysis in TIMP-3-overexpressing HEK293 cells; LRP-1 inactivation comparison","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 — unbiased MS proteomics with genetic controls, dual mechanistic findings (ADAM10 inhibition + LRP-1 competition)","pmids":["30279425"],"is_preprint":false},{"year":2012,"finding":"TIMP3, but not TIMP2, inhibits pro-MMP2 activation in kidney; TIMP3 deficiency selectively activates TACE, caspase-3, and MAPK pathways in obstructed kidney while TIMP2 deficiency reduces MMP2 activation, demonstrating divergent and contrasting roles in renal injury.","method":"TIMP2-/- and TIMP3-/- mice with unilateral ureteral obstruction; gelatin zymography; TACE activity assays; caspase-3 assays","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 2 — comparative KO mouse models with multiple enzymatic assays, defined mechanistic divergence","pmids":["23760282"],"is_preprint":false},{"year":2011,"finding":"TIMP3 deficiency accelerates mammary gland involution through TNF dysregulation, earlier caspase-3 activation, and mitochondrial apoptosis; TNF deficiency abrogates caspase-3 activation but increases macrophage/T-cell infiltration, demonstrating that TIMP3 differentially controls apoptosis (via TNF) and inflammatory cell influx through distinct mechanisms.","method":"Timp3-/- and Timp3-/-/Tnf-/- double-KO mice during mammary involution; caspase assays; histology; flow cytometry","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — genetic double-KO epistasis with multiple mechanistic readouts","pmids":["22053204"],"is_preprint":false},{"year":2012,"finding":"Stromal (hepatocyte-derived) TIMP3 regulates basal hepatic lymphocyte populations; TIMP3 deficiency leads to spontaneous accumulation and activation of hepatic CD4+, CD8+, and NKT cells and exacerbated Th1 cytokine response dependent on TNF signaling during Con A-induced autoimmune hepatitis. Bone marrow chimeras confirmed the stromal rather than hematopoietic source of protective TIMP3.","method":"Timp3-/- mice; bone marrow chimeras; Con A hepatitis model; flow cytometry; cytokine measurements","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 — bone marrow chimera epistasis, KO model, multiple immune cell readouts","pmids":["22323541"],"is_preprint":false},{"year":2014,"finding":"TIMP3 and TIMP2 play differential roles in cardiac hypertrophy and fibrosis: TIMP3 deficiency causes excess fibrosis (via MMP-independent post-translational stabilization of collagen by osteopontin and SPARC), while TIMP2 deficiency causes hypertrophy; both independently cause diastolic dysfunction.","method":"TIMP2-/- and TIMP3-/- mice with angiotensin II infusion; echocardiography; co-culture assays; Western blot for matricellular proteins; collagen crosslinking analysis","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — comparative KO models, in vitro co-culture mechanistic studies, multiple orthogonal assays","pmids":["24692173"],"is_preprint":false},{"year":1995,"finding":"The human TIMP-3 gene is a TATA-less, 5-exon gene mapped to chromosome 22q13.1; its promoter contains multiple Sp1 sites sufficient for basal expression, while the region between -463 and -112 bp confers serum inducibility and cell-cycle regulation.","method":"Genomic cloning, somatic cell hybrid mapping, promoter-reporter deletion analysis in cell cycle studies","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — direct structural and functional promoter analysis with deletion mapping","pmids":["7487894"],"is_preprint":false},{"year":2003,"finding":"The SFD mutation S156C in TIMP3 does not impair MMP2 inhibitory activity but causes the protein to form dimers and accumulate in the ECM; this accumulation is not due to altered turnover rate and does not affect MMP2 or MMP9 levels or activation in patient-derived fibroblasts.","method":"Immortalized fibroblast lines from Timp3-/- and Timp3S156C/S156C mice; gelatin zymography; ECM immunoblot; turnover assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — cell-based biochemical assays in genetically defined fibroblast lines, single lab","pmids":["12942551"],"is_preprint":false},{"year":2008,"finding":"The SFD-associated S156C mutation in TIMP3 does not impair inhibitory activity against TACE, ADAMTS4/5, or aggrecan-cleaving MMPs, nor its anti-angiogenic properties or VEGF/VEGFR2 blocking activity, suggesting SFD pathogenesis involves loss of a distinct non-protease-inhibitory function rather than imbalanced protease activity.","method":"Timp3S156C knock-in mice; TACE, ADAMTS4/5, MMP activity assays; fibrin bead angiogenesis assay; VEGF-VEGFR2 binding assay with recombinant proteins","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"High","confidence_rationale":"Tier 1 — multiple in vitro enzymatic assays and functional rescue with recombinant proteins in genetically defined mouse model","pmids":["18295466"],"is_preprint":false},{"year":2014,"finding":"Loss of TIMP3 in ApoE-/- mice increases atherosclerosis with greater macrophage infiltration, elevated MCP-1, and polarization of macrophages toward an inflammatory M1/Gr1+ phenotype, demonstrating a role for TIMP3 in restraining macrophage inflammatory polarization during atherogenesis.","method":"ApoE-/-Timp3-/- double-KO mice; en face aorta analysis; flow cytometry of macrophage subsets; serum MCP-1 measurement","journal":"Atherosclerosis","confidence":"High","confidence_rationale":"Tier 2 — genetic double-KO model with multiple mechanistic readouts, macrophage phenotyping","pmids":["24943223"],"is_preprint":false},{"year":2017,"finding":"Hepatocyte-specific TIMP3 overexpression improves glucose metabolism, hepatic fatty acid oxidation, and cholesterol homeostasis during high-fat diet; hepatocyte-specific Adam17 knockout (A17LKO), but not myeloid-specific Adam17 deletion, similarly reduces hepatic steatosis, establishing TIMP3 acts through hepatocyte ADAM17 inhibition to limit NAFLD and hepatocarcinogenesis.","method":"AlbT3 (hepatocyte TIMP3 overexpression) and A17LKO/A17MKO (cell-type-specific Adam17 KO) mice on HFD; metabolic assays; diethylnitrosamine tumor model","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific genetic epistasis (overexpression + conditional KO), multiple metabolic readouts","pmids":["28751722"],"is_preprint":false},{"year":2018,"finding":"TIMP3 expression is regulated by a circadian CLOCK-dependent mechanism in human keratinocytes; CLOCK knockdown reduces TIMP3 expression and inversely increases MMP-1, TNF-α, CXCL1, and IL-8 via C/EBPα; UVB exposure suppresses CLOCK and TIMP3, and TIMP3 knockdown or overexpression modulates UVB-induced TNF-α secretion.","method":"CLOCK siRNA knockdown; TIMP3 overexpression/knockdown in keratinocytes; ELISA for secreted cytokines; promoter analysis","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple genetic manipulations with functional readouts, single lab","pmids":["29180440"],"is_preprint":false},{"year":2014,"finding":"Human cytomegalovirus (CMV) infection downregulates TIMP3 expression through upregulated cellular and CMV-encoded microRNAs, causing increased ADAM17 and MMP14 activity and enhanced shedding of the NKG2D ligand MICA to evade NK cell recognition.","method":"CMV infection of cells; miRNA expression analysis; metalloprotease activity assays; MICA shedding ELISA; soluble MICA detection in patient serum","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 — cell-based mechanistic dissection with functional immune readout, human serum validation","pmids":["24973455"],"is_preprint":false},{"year":2016,"finding":"KDM1A (histone demethylase) represses TIMP3 transcription by removing H3K4me2 at the TIMP3 promoter; KDM1A overexpression promotes NSCLC cell invasion and migration, which is rescued by TIMP3 overexpression; TIMP3 in turn suppresses MMP2 expression and JNK phosphorylation.","method":"KDM1A KD/OE in NSCLC cells; ChIP for H3K4me2 at TIMP3 promoter; invasion/migration assays; TIMP3 rescue experiments; pharmacological inhibition","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP mechanistic validation, genetic rescue experiments, single lab","pmids":["27058897"],"is_preprint":false},{"year":2011,"finding":"TIMP3 promotes apoptotic cell death in small cell lung cancer cells that lack functional caspase-8 (adenovirally delivered TIMP3), indicating TIMP3 can induce apoptosis through a caspase-8-independent pathway in suspension-growing tumor cells.","method":"Adenoviral TIMP3 delivery to suspension-growing SCLC cell lines SW2 and N417; apoptosis assays; caspase-8 functional analysis","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — clean loss-of-function/gain-of-function with mechanistic pathway exclusion, single lab","pmids":["20473894"],"is_preprint":false},{"year":2019,"finding":"HDAC9 promotes trophoblast cell migration and invasion by repressing TIMP3 through promoter histone hypoacetylation; HDAC9 knockdown increases histone acetylation at the TIMP3 promoter (by ChIP-qPCR) and upregulates TIMP3, inhibiting trophoblast invasion in preeclampsia.","method":"HDAC9 siRNA knockdown; ChIP-qPCR for TIMP3 promoter histone acetylation; transwell migration/invasion assays","journal":"American journal of hypertension","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-qPCR mechanistic validation, functional rescue, single lab","pmids":["30715128"],"is_preprint":false},{"year":2021,"finding":"MSI1 (Musashi1) RNA-binding protein directly suppresses TIMP3 expression, reducing TIMP3-mediated inhibition of MMP9, thereby promoting invadopodia formation and ECM degradation in breast cancer metastasis; TIMP3 and MSI1 expression are inversely correlated in clinical specimens.","method":"MSI1 KD/OE in mammary cancer cells; invadopodia formation assays; MMP9 activity; TIMP3 rescue; clinical tissue correlation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic cascade established by KD/rescue experiments with functional readout, clinical validation","pmids":["34155343"],"is_preprint":false},{"year":2009,"finding":"In periovulatory granulosa cells, hCG induces biphasic TIMP3 expression via PKA, PKC, MAPK, progesterone receptor, and EGF receptor pathways; siRNA knockdown of Timp3 reduces hCG-induced progesterone levels by ~20%, indicating TIMP3 regulates steroidogenesis during ovulation.","method":"Rat granulosa cell isolation; pharmacological pathway inhibitors; Timp3-specific siRNA; progesterone measurement; microarray analysis","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA functional knockdown with defined steroidogenic readout, multiple pathway inhibitors","pmids":["19389837"],"is_preprint":false}],"current_model":"TIMP3 is an ECM-bound broad-spectrum metalloproteinase inhibitor that blocks MMPs, aggrecanases (ADAMTS4/5), ADAM10, and ADAM17/TACE with sub-nanomolar potency; its extracellular bioavailability is regulated by LRP-1-mediated endocytosis; by restraining TACE activity it controls TNF-α shedding, EGFR ligand release, and NKG2D ligand shedding; it additionally blocks VEGFR2 signaling to suppress angiogenesis and regulates cerebral arterial tone via the ADAM17/HB-EGF/KV channel axis; loss of TIMP3 causes spontaneous cardiomyopathy, renal fibrosis, and vascular dysfunction through unchecked MMP and TACE activity, establishing it as a critical extracellular brake on protease-driven tissue remodeling and inflammation."},"narrative":{"teleology":[{"year":1995,"claim":"Establishing the genomic architecture of TIMP3 — a TATA-less gene on chromosome 22q13.1 with Sp1-dependent basal transcription and serum-inducible upstream elements — provided the foundation for understanding its transcriptional regulation.","evidence":"Genomic cloning, somatic cell hybrid mapping, and promoter-reporter deletion analysis in cell cycle studies","pmids":["7487894"],"confidence":"High","gaps":["Transcription factor binding to the serum-responsive element not identified","No chromatin-level regulation addressed"]},{"year":1997,"claim":"Demonstrating that TIMP3 protein is uniquely sequestered in the ECM (Bruch's membrane) rather than being secreted into medium explained why TIMP3 mutations cause the retinal-specific Sorsby's fundus dystrophy, unlike other TIMPs.","evidence":"RT-PCR, Northern, Western blot, and immunohistochemistry of human retina/choroid and cultured RPE cells","pmids":["9068940"],"confidence":"High","gaps":["Molecular determinants of ECM binding not identified","Whether ECM sequestration differs across tissue types not resolved"]},{"year":2000,"claim":"Identifying TIMP3 as the sole TIMP capable of inhibiting both ADAM10 and TACE (ADAM17) at sub-nanomolar potency expanded its functional scope beyond MMP inhibition to regulation of ADAMs-mediated ectodomain shedding.","evidence":"Quenched fluorescent substrate assay and myelin basic protein degradation assay with recombinant ADAM10 catalytic domain","pmids":["10818225"],"confidence":"High","gaps":["Structural basis for TIMP3 selectivity toward ADAMs not determined","In vivo relevance of ADAM10 inhibition not yet shown"]},{"year":2001,"claim":"Showing that the N-terminal domain of TIMP3 potently inhibits aggrecanases ADAMTS4 and ADAMTS5 (Ki < 1 nM) established TIMP3 as the first known endogenous regulator of cartilage-degrading aggrecanases.","evidence":"In vitro enzymatic inhibition assay with recombinant N-terminal TIMP3 domain","pmids":["11278243"],"confidence":"High","gaps":["In vivo cartilage protection by endogenous TIMP3 not demonstrated","Aggrecanase inhibition mechanism at the structural level not resolved"]},{"year":2003,"claim":"Analyzing the Sorsby's fundus dystrophy S156C mutation revealed it causes TIMP3 dimerization and ECM accumulation without impairing MMP2 inhibition, redirecting pathogenic models away from simple loss of protease inhibitory function.","evidence":"Immortalized fibroblast lines from Timp3S156C/S156C mice; gelatin zymography; ECM immunoblot; turnover assays","pmids":["12942551"],"confidence":"Medium","gaps":["Single lab study","Downstream consequence of ECM accumulation on retinal physiology not tested","Whether dimerization affects ADAM inhibition not assessed"]},{"year":2004,"claim":"Timp3-knockout mice developing spontaneous dilated cardiomyopathy with elevated MMP-9 and TNF-α provided the first in vivo proof that TIMP3 is indispensable for maintaining myocardial matrix homeostasis.","evidence":"Targeted Timp3-KO mice evaluated longitudinally; gelatinase bioassay; echocardiography and histology","pmids":["15262835"],"confidence":"High","gaps":["Whether cardiomyopathy is MMP- or TACE-dependent not dissected","Cell-type-specific contributions within heart not determined"]},{"year":2005,"claim":"Genetic epistasis placing TIMP3 upstream of TACE/TNF-α in metabolic disease — with pharmacological TACE inhibition rescuing vascular inflammation in TIMP3-deficient mice — established the TIMP3→TACE→TNF-α axis as a central inflammatory circuit.","evidence":"Insr+/-Timp3+/- double heterozygous mice; TACE activity assays; pharmacological TACE inhibitor rescue","pmids":["16294222"],"confidence":"High","gaps":["Contribution of other TACE substrates besides TNF-α not dissected","Human metabolic disease relevance not directly tested"]},{"year":2008,"claim":"Two key advances refined the inhibitory mechanism: full-length TIMP3 was shown to be required for ADAM10 inhibition (unlike for MMPs/ADAM17), and the S156C SFD mutation was found to preserve all tested protease-inhibitory and anti-angiogenic functions, suggesting SFD involves a non-protease-inhibitory mechanism.","evidence":"In vitro domain-truncation inhibition assays; Timp3S156C knock-in mice with TACE, ADAMTS, MMP, and VEGFR2-binding assays","pmids":["18215140","18295466"],"confidence":"High","gaps":["C-terminal structural contacts with ADAM10 not mapped","The non-protease-inhibitory pathogenic mechanism in SFD remains unidentified"]},{"year":2009,"claim":"Double-KO epistasis (Timp3−/−/TNFα−/−) in renal obstruction proved that TIMP3 restrains kidney fibrosis via dual TACE/TNF-α and MMP-2 axes, with TNF-α deletion rescuing most inflammatory injury.","evidence":"TIMP3−/− and TIMP3−/−/TNFα−/− double-KO mice with unilateral ureteral obstruction; TACE activity; gelatin zymography","pmids":["19406980"],"confidence":"High","gaps":["Relative contribution of TNF-dependent vs MMP-dependent fibrosis not fully quantified","Cell-type-specific source of renal TIMP3 not identified"]},{"year":2011,"claim":"During mammary involution, TIMP3 differentially controls apoptosis (via TNF) and inflammatory cell influx through distinct mechanisms, as shown by double-KO epistasis where TNF deletion abrogated caspase-3 activation but paradoxically increased macrophage/T-cell infiltration.","evidence":"Timp3−/− and Timp3−/−/Tnf−/− double-KO mice during mammary involution; caspase assays; flow cytometry","pmids":["22053204"],"confidence":"High","gaps":["Identity of the TNF-independent inflammatory target protease not established","Whether this bifurcation applies in other tissues not tested"]},{"year":2012,"claim":"Multiple 2012 studies converged on how TIMP3 integrates into tissue-specific protease control: TACE dimerization governs TIMP3 association at the cell surface, pericyte-derived TIMP3 stabilizes capillaries via ADAMTS1 inhibition, stromal TIMP3 regulates hepatic immune populations, and TIMP3 and TIMP2 have divergent roles in renal injury.","evidence":"TACE dimerization/co-IP assays; 3D capillary tube networks with pericytes; bone marrow chimeras in Con A hepatitis; comparative TIMP2−/−/TIMP3−/− kidney models","pmids":["22550340","22383695","22323541","23760282"],"confidence":"High","gaps":["Structural basis of TACE dimer–TIMP3 interaction unknown","Whether pericyte TIMP3 acts through the same TACE/TNF axis not established"]},{"year":2013,"claim":"In diabetic nephropathy, TIMP3 loss activates ADAM17 leading to elevated STAT1 that represses FoxO1 and autophagy; TIMP3 re-expression rescues this cascade, establishing TIMP3→ADAM17→STAT1→FoxO1 as a signaling axis in metabolic kidney disease.","evidence":"Diabetic Timp3−/− mice; microarray; mesangial cell re-expression; STAT1 siRNA rescue; human kidney biopsies","pmids":["23401241"],"confidence":"High","gaps":["Which ADAM17 substrate mediates STAT1 activation not identified","Whether this axis operates in non-renal diabetic complications not tested"]},{"year":2014,"claim":"TIMP3's anti-inflammatory role was extended to atherosclerosis (macrophage M1 polarization in ApoE−/−Timp3−/− mice) and cardiac fibrosis (MMP-independent collagen stabilization via osteopontin/SPARC), revealing protease-independent functions.","evidence":"ApoE−/−Timp3−/− mice with en face aorta analysis and macrophage flow cytometry; TIMP3−/− mice with AngII infusion and collagen crosslinking analysis","pmids":["24943223","24692173"],"confidence":"High","gaps":["Mechanism by which TIMP3 deficiency elevates osteopontin/SPARC not resolved","Direct protease target responsible for macrophage polarization not identified"]},{"year":2016,"claim":"Three breakthroughs in 2016 clarified TIMP3 bioavailability and vascular function: LRP-1 cluster II mediates TIMP3 endocytosis and a soluble minireceptor (T3TRAP) blocks this to increase extracellular TIMP3; elevated TIMP3 in CADASIL causes cerebrovascular dysfunction via ADAM17/HB-EGF/KV channel axis; and Timp3 haploinsufficiency rescues CADASIL cerebral blood flow deficits.","evidence":"Biochemical LRP-1 binding assays and MS secretome; CADASIL mouse pharmacological/genetic rescue with CBF measurement and patch-clamp electrophysiology; TgNotch3R169C × Timp3+/− mice","pmids":["27476612","27476853","26648042"],"confidence":"High","gaps":["Whether T3TRAP is effective in vivo not demonstrated","Whether TIMP3 accumulation in CADASIL is the sole pathogenic mediator vs other trapped ECM proteins","Structural basis of LRP-1 cluster II–TIMP3 interaction not resolved"]},{"year":2017,"claim":"Hepatocyte-specific TIMP3 overexpression phenocopied hepatocyte-specific Adam17 deletion in protecting against NAFLD and hepatocarcinogenesis, confirming the TIMP3–ADAM17 axis operates cell-autonomously in hepatocytes to control lipid metabolism.","evidence":"AlbT3 and A17LKO conditional mice on HFD; metabolic assays; diethylnitrosamine tumor model","pmids":["28751722"],"confidence":"High","gaps":["ADAM17 substrates responsible for hepatic lipid accumulation not identified","Whether myeloid TIMP3 has independent liver-protective roles not resolved"]},{"year":2018,"claim":"Two studies linked TIMP3 to pericyte TGF-β signaling and to LRP-1-mediated secretome remodeling: pericyte ALK5 drives TIMP3 expression to suppress perivascular MMP activity and prevent germinal matrix hemorrhage, while TIMP3 overexpression competes with other LRP-1 cargo (TIMP-1, MIF, SPARC) for endocytosis.","evidence":"Conditional pericyte Alk5-KO mice with TIMP3 rescue; MS secretome in TIMP3-overexpressing HEK293 with LRP-1 inactivation comparison","pmids":["29456135","30279425"],"confidence":"High","gaps":["Whether TIMP3 competition for LRP-1 is physiologically relevant at endogenous expression levels","Downstream consequences of altered MIF/SPARC clearance not tested"]},{"year":null,"claim":"Key unresolved questions include: the structural basis for TIMP3's selective inhibition of ADAMs versus MMPs; the identity of the non-protease-inhibitory function lost in Sorsby's fundus dystrophy; the cell-type-specific transcriptional and post-transcriptional regulatory network controlling TIMP3 levels in vivo; and the therapeutic potential of modulating TIMP3 bioavailability (e.g., via LRP-1 blockade) in disease.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No crystal structure of TIMP3 in complex with an ADAM family member","SFD pathogenic mechanism remains undefined despite exclusion of protease-inhibitory loss","In vivo therapeutic efficacy of T3TRAP or similar LRP-1-blocking strategies not tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,12]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[13]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[13,22]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[13,15,16]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,4,5,10,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,19,24,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3,14,25]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[7,18,29]}],"complexes":[],"partners":["ADAM17","ADAM10","ADAMTS4","ADAMTS5","LRP1","MMP9","MMP2","KDR"],"other_free_text":[]},"mechanistic_narrative":"TIMP3 is an extracellular matrix-sequestered metalloproteinase inhibitor that serves as a master brake on protease-driven tissue remodeling, inflammation, and vascular homeostasis. It inhibits MMPs, aggrecanases (ADAMTS4/5), ADAM10, and ADAM17/TACE with sub-nanomolar potency, using its N-terminal domain for MMP and aggrecanase inhibition but requiring its full-length structure for ADAM10 blockade [PMID:11278243, PMID:10818225, PMID:18215140]. By suppressing TACE activity, TIMP3 controls TNF-α shedding, EGFR ligand release, NKG2D ligand shedding, and downstream STAT1/FoxO1 signaling; its extracellular bioavailability is regulated by LRP-1-mediated endocytosis, and its loss causes spontaneous dilated cardiomyopathy, renal fibrosis, accelerated atherosclerosis, and metabolic disease through unchecked TACE and MMP activity [PMID:15262835, PMID:16294222, PMID:19406980, PMID:27476612, PMID:23401241, PMID:24943223]. Mutations in TIMP3 (e.g., S156C) cause Sorsby's fundus dystrophy, linked to its unique ECM deposition in Bruch's membrane, though the S156C mutation preserves protease-inhibitory function and instead causes abnormal dimerization and ECM accumulation [PMID:9068940, PMID:12942551, PMID:18295466]."},"prefetch_data":{"uniprot":{"accession":"P35625","full_name":"Metalloproteinase inhibitor 3","aliases":["Protein MIG-5","Tissue inhibitor of metalloproteinases 3","TIMP-3"],"length_aa":211,"mass_kda":24.1,"function":"Mediates a variety of processes including matrix regulation and turnover, inflammation, and angiogenesis, through reversible inhibition of zinc protease superfamily enzymes, primarily matrix metalloproteinases (MMPs). Regulates extracellular matrix (ECM) remodeling through inhibition of matrix metalloproteinases (MMP) including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15. Additionally, modulates the processing of amyloid precursor protein (APP) and apolipoprotein E receptor ApoER2 by inhibiting two alpha-secretases ADAM10 and ADAM17 (PubMed:17913923). Functions as a tumor suppressor and a potent inhibitor of angiogenesis. Exerts its anti-angiogenic effect by directly interacting with vascular endothelial growth factor (VEGF) receptor-2/KDR, preventing its binding to the VEGFA ligand (PubMed:12652295). Selectively induces apoptosis in angiogenic endothelial cells through a caspase-independent cell death pathway (PubMed:25558000). Mechanistically, inhibits matrix-induced focal adhesion kinase PTK2 tyrosine phosphorylation and association with paxillin/PXN and disrupts the incorporation of ITGB3, PTK2 and PXN into focal adhesion contacts on the matrix (PubMed:25558000)","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/P35625/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TIMP3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"TMED10","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TIMP3","total_profiled":1310},"omim":[{"mim_id":"613105","title":"CHOROIDAL DYSTROPHY, CENTRAL AREOLAR 2; CACD2","url":"https://www.omim.org/entry/613105"},{"mim_id":"605670","title":"LATE-ONSET RETINAL DEGENERATION; LORD","url":"https://www.omim.org/entry/605670"},{"mim_id":"605020","title":"VISUAL SYSTEM HOMEOBOX 1; VSX1","url":"https://www.omim.org/entry/605020"},{"mim_id":"601915","title":"TISSUE INHIBITOR OF METALLOPROTEINASE 4; TIMP4","url":"https://www.omim.org/entry/601915"},{"mim_id":"601548","title":"EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 1; EFEMP1","url":"https://www.omim.org/entry/601548"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TIMP3"},"hgnc":{"alias_symbol":[],"prev_symbol":["SFD"]},"alphafold":{"accession":"P35625","domains":[{"cath_id":"2.40.50.120","chopping":"26-126","consensus_level":"medium","plddt":96.8866,"start":26,"end":126},{"cath_id":"3.90.370.10","chopping":"128-199","consensus_level":"medium","plddt":90.3857,"start":128,"end":199}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35625","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35625-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35625-F1-predicted_aligned_error_v6.png","plddt_mean":87.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TIMP3","jax_strain_url":"https://www.jax.org/strain/search?query=TIMP3"},"sequence":{"accession":"P35625","fasta_url":"https://rest.uniprot.org/uniprotkb/P35625.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35625/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35625"}},"corpus_meta":[{"pmid":"11278243","id":"PMC_11278243","title":"TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278243","citation_count":400,"is_preprint":false},{"pmid":"10818225","id":"PMC_10818225","title":"The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10818225","citation_count":334,"is_preprint":false},{"pmid":"22383695","id":"PMC_22383695","title":"Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury.","date":"2012","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/22383695","citation_count":168,"is_preprint":false},{"pmid":"27756793","id":"PMC_27756793","title":"MicroRNA-181b Controls Atherosclerosis and Aneurysms Through Regulation of TIMP-3 and Elastin.","date":"2016","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/27756793","citation_count":147,"is_preprint":false},{"pmid":"16294222","id":"PMC_16294222","title":"Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16294222","citation_count":141,"is_preprint":false},{"pmid":"15262835","id":"PMC_15262835","title":"TIMP-3 deficiency leads to dilated cardiomyopathy.","date":"2004","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/15262835","citation_count":132,"is_preprint":false},{"pmid":"9164653","id":"PMC_9164653","title":"A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth.","date":"1996","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/9164653","citation_count":129,"is_preprint":false},{"pmid":"22550340","id":"PMC_22550340","title":"TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association.","date":"2012","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22550340","citation_count":125,"is_preprint":false},{"pmid":"19406980","id":"PMC_19406980","title":"Loss of TIMP3 enhances interstitial nephritis and fibrosis.","date":"2009","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19406980","citation_count":119,"is_preprint":false},{"pmid":"32612540","id":"PMC_32612540","title":"Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32612540","citation_count":115,"is_preprint":false},{"pmid":"24692173","id":"PMC_24692173","title":"Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction.","date":"2014","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/24692173","citation_count":99,"is_preprint":false},{"pmid":"21983937","id":"PMC_21983937","title":"Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.","date":"2011","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/21983937","citation_count":99,"is_preprint":false},{"pmid":"23401241","id":"PMC_23401241","title":"Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay.","date":"2013","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23401241","citation_count":90,"is_preprint":false},{"pmid":"12388270","id":"PMC_12388270","title":"Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3.","date":"2002","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12388270","citation_count":89,"is_preprint":false},{"pmid":"32896063","id":"PMC_32896063","title":"CircFNDC3B sequestrates miR-937-5p to derepress TIMP3 and inhibit colorectal cancer progression.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32896063","citation_count":83,"is_preprint":false},{"pmid":"31927006","id":"PMC_31927006","title":"N6-methyladenosine ALKBH5 promotes non-small cell lung cancer progress by regulating TIMP3 stability.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31927006","citation_count":79,"is_preprint":false},{"pmid":"26872030","id":"PMC_26872030","title":"The Angiogenic Effect of microRNA-21 Targeting TIMP3 through the Regulation of MMP2 and MMP9.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26872030","citation_count":77,"is_preprint":false},{"pmid":"14532978","id":"PMC_14532978","title":"Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.","date":"2003","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14532978","citation_count":76,"is_preprint":false},{"pmid":"23797704","id":"PMC_23797704","title":"Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs.","date":"2013","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/23797704","citation_count":76,"is_preprint":false},{"pmid":"26648042","id":"PMC_26648042","title":"Reducing Timp3 or vitronectin ameliorates disease manifestations in CADASIL mice.","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26648042","citation_count":75,"is_preprint":false},{"pmid":"21339735","id":"PMC_21339735","title":"TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21339735","citation_count":72,"is_preprint":false},{"pmid":"9152225","id":"PMC_9152225","title":"Exclusion of TIMP3 as a candidate locus in age-related macular degeneration.","date":"1997","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/9152225","citation_count":71,"is_preprint":false},{"pmid":"12845640","id":"PMC_12845640","title":"Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12845640","citation_count":70,"is_preprint":false},{"pmid":"17913923","id":"PMC_17913923","title":"The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis.","date":"2007","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17913923","citation_count":68,"is_preprint":false},{"pmid":"31624299","id":"PMC_31624299","title":"Loss of TIMP3 by promoter methylation of Sp1 binding site promotes oral cancer metastasis.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31624299","citation_count":67,"is_preprint":false},{"pmid":"30281655","id":"PMC_30281655","title":"TIMP3 and TIMP1 are risk genes for bicuspid aortic valve and aortopathy in Turner syndrome.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30281655","citation_count":66,"is_preprint":false},{"pmid":"25558000","id":"PMC_25558000","title":"Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism.","date":"2015","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/25558000","citation_count":66,"is_preprint":false},{"pmid":"29796115","id":"PMC_29796115","title":"miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.","date":"2018","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/29796115","citation_count":62,"is_preprint":false},{"pmid":"27476853","id":"PMC_27476853","title":"Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27476853","citation_count":62,"is_preprint":false},{"pmid":"27383203","id":"PMC_27383203","title":"Smad2/3/4 Pathway Contributes to TGF-β-Induced MiRNA-181b Expression to Promote Gastric Cancer Metastasis by Targeting Timp3.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27383203","citation_count":58,"is_preprint":false},{"pmid":"27386931","id":"PMC_27386931","title":"Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.","date":"2016","source":"Otolaryngologia polska = The Polish otolaryngology","url":"https://pubmed.ncbi.nlm.nih.gov/27386931","citation_count":57,"is_preprint":false},{"pmid":"7487894","id":"PMC_7487894","title":"Structure of the human TIMP-3 gene and its cell cycle-regulated promoter.","date":"1995","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7487894","citation_count":55,"is_preprint":false},{"pmid":"23760282","id":"PMC_23760282","title":"TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury.","date":"2013","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/23760282","citation_count":55,"is_preprint":false},{"pmid":"25301980","id":"PMC_25301980","title":"Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25301980","citation_count":54,"is_preprint":false},{"pmid":"9068940","id":"PMC_9068940","title":"Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid.","date":"1997","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/9068940","citation_count":51,"is_preprint":false},{"pmid":"29177591","id":"PMC_29177591","title":"MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3.","date":"2017","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/29177591","citation_count":49,"is_preprint":false},{"pmid":"25065733","id":"PMC_25065733","title":"HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation.","date":"2014","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25065733","citation_count":48,"is_preprint":false},{"pmid":"29196060","id":"PMC_29196060","title":"miR-365 promotes diabetic retinopathy through inhibiting Timp3 and increasing oxidative stress.","date":"2017","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/29196060","citation_count":47,"is_preprint":false},{"pmid":"24876280","id":"PMC_24876280","title":"MMP-2, MMP-3, TIMP-1, TIMP-2, and TIMP-3 protein levels in human aqueous humor: relationship with axial length.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24876280","citation_count":46,"is_preprint":false},{"pmid":"24943223","id":"PMC_24943223","title":"Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice.","date":"2014","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/24943223","citation_count":44,"is_preprint":false},{"pmid":"22896043","id":"PMC_22896043","title":"Loss of TIMP3 selectively exacerbates diabetic nephropathy.","date":"2012","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22896043","citation_count":42,"is_preprint":false},{"pmid":"24632095","id":"PMC_24632095","title":"Expression of ADAMTs-5 and TIMP-3 in the condylar cartilage of rats induced by experimentally created osteoarthritis.","date":"2014","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/24632095","citation_count":41,"is_preprint":false},{"pmid":"9184186","id":"PMC_9184186","title":"TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma.","date":"1997","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9184186","citation_count":40,"is_preprint":false},{"pmid":"32724322","id":"PMC_32724322","title":"Curcumin Inhibits Hepatocellular Carcinoma via Regulating miR-21/TIMP3 Axis.","date":"2020","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/32724322","citation_count":40,"is_preprint":false},{"pmid":"27058897","id":"PMC_27058897","title":"KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27058897","citation_count":40,"is_preprint":false},{"pmid":"16507410","id":"PMC_16507410","title":"DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma.","date":"2005","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/16507410","citation_count":39,"is_preprint":false},{"pmid":"32271187","id":"PMC_32271187","title":"Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions.","date":"2020","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32271187","citation_count":39,"is_preprint":false},{"pmid":"24973455","id":"PMC_24973455","title":"Altered microRNA expression after infection with human cytomegalovirus leads to TIMP3 downregulation and increased shedding of metalloprotease substrates, including MICA.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24973455","citation_count":39,"is_preprint":false},{"pmid":"29456135","id":"PMC_29456135","title":"Pericyte ALK5/TIMP3 Axis Contributes to Endothelial Morphogenesis in the Developing Brain.","date":"2018","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/29456135","citation_count":38,"is_preprint":false},{"pmid":"36164322","id":"PMC_36164322","title":"Exosomal miR-452-5p Induce M2 Macrophage Polarization to Accelerate Hepatocellular Carcinoma Progression by Targeting TIMP3.","date":"2022","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36164322","citation_count":38,"is_preprint":false},{"pmid":"28854428","id":"PMC_28854428","title":"MicroRNA-222 Promotes the Proliferation of Pulmonary Arterial Smooth Muscle Cells by Targeting P27 and TIMP3.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28854428","citation_count":38,"is_preprint":false},{"pmid":"25171061","id":"PMC_25171061","title":"TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25171061","citation_count":37,"is_preprint":false},{"pmid":"28236165","id":"PMC_28236165","title":"Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3.","date":"2017","source":"Cardiovascular engineering and technology","url":"https://pubmed.ncbi.nlm.nih.gov/28236165","citation_count":37,"is_preprint":false},{"pmid":"11879143","id":"PMC_11879143","title":"Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy.","date":"2002","source":"Archives of ophthalmology (Chicago, Ill. : 1960)","url":"https://pubmed.ncbi.nlm.nih.gov/11879143","citation_count":35,"is_preprint":false},{"pmid":"31877820","id":"PMC_31877820","title":"The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31877820","citation_count":34,"is_preprint":false},{"pmid":"18215140","id":"PMC_18215140","title":"The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.","date":"2008","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18215140","citation_count":34,"is_preprint":false},{"pmid":"32309847","id":"PMC_32309847","title":"MiR-770-5p facilitates podocyte apoptosis and inflammation in diabetic nephropathy by targeting TIMP3.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32309847","citation_count":34,"is_preprint":false},{"pmid":"23023649","id":"PMC_23023649","title":"Heterogeneous epigenetic regulation of TIMP3 in prostate cancer.","date":"2012","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/23023649","citation_count":34,"is_preprint":false},{"pmid":"25819812","id":"PMC_25819812","title":"MiR-191 modulates malignant transformation of endometriosis through regulating TIMP3.","date":"2015","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/25819812","citation_count":33,"is_preprint":false},{"pmid":"28539838","id":"PMC_28539838","title":"Andrographolide Inhibits Angiogenesis by Inhibiting the Mir-21-5p/TIMP3 Signaling Pathway.","date":"2017","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28539838","citation_count":32,"is_preprint":false},{"pmid":"20473894","id":"PMC_20473894","title":"TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20473894","citation_count":32,"is_preprint":false},{"pmid":"30715128","id":"PMC_30715128","title":"Dysregulation of HDAC9 Represses Trophoblast Cell Migration and Invasion Through TIMP3 Activation in Preeclampsia.","date":"2019","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/30715128","citation_count":31,"is_preprint":false},{"pmid":"31933879","id":"PMC_31933879","title":"LncRNA TUG1 ameliorates diabetic nephropathy by inhibiting miR-21 to promote TIMP3-expression.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31933879","citation_count":31,"is_preprint":false},{"pmid":"19389837","id":"PMC_19389837","title":"Regulation and function of tissue inhibitor of metalloproteinase (TIMP) 1 and TIMP3 in periovulatory rat granulosa cells.","date":"2009","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19389837","citation_count":31,"is_preprint":false},{"pmid":"26749283","id":"PMC_26749283","title":"TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26749283","citation_count":30,"is_preprint":false},{"pmid":"33960555","id":"PMC_33960555","title":"CircSLC7A2 protects against osteoarthritis through inhibition of the miR-4498/TIMP3 axis.","date":"2021","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/33960555","citation_count":30,"is_preprint":false},{"pmid":"16989765","id":"PMC_16989765","title":"A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy.","date":"2006","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/16989765","citation_count":30,"is_preprint":false},{"pmid":"30223084","id":"PMC_30223084","title":"Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Société francophone du diabète (SFD), Société francaise d'endocrinologie (SFE), Société francophone de transplantation (SFT) and Société française de néphrologie - dialyse - transplantation (SFNDT).","date":"2018","source":"Diabetes & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30223084","citation_count":29,"is_preprint":false},{"pmid":"22323541","id":"PMC_22323541","title":"Stromal TIMP3 regulates liver lymphocyte populations and provides protection against Th1 T cell-driven autoimmune hepatitis.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22323541","citation_count":29,"is_preprint":false},{"pmid":"12942551","id":"PMC_12942551","title":"Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12942551","citation_count":28,"is_preprint":false},{"pmid":"16900752","id":"PMC_16900752","title":"Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter.","date":"2006","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16900752","citation_count":28,"is_preprint":false},{"pmid":"32631441","id":"PMC_32631441","title":"Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage.","date":"2020","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/32631441","citation_count":27,"is_preprint":false},{"pmid":"34390329","id":"PMC_34390329","title":"A circular RNA, circSMARCA5, inhibits prostate cancer proliferative, migrative, and invasive capabilities via the miR-181b-5p/miR-17-3p-TIMP3 axis.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34390329","citation_count":27,"is_preprint":false},{"pmid":"23172037","id":"PMC_23172037","title":"Promoter hypomethylation of TIMP3 is associated with pre-eclampsia in a Chinese population.","date":"2012","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23172037","citation_count":27,"is_preprint":false},{"pmid":"28751722","id":"PMC_28751722","title":"Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28751722","citation_count":26,"is_preprint":false},{"pmid":"29180440","id":"PMC_29180440","title":"TIMP3 is a CLOCK-dependent diurnal gene that inhibits the expression of UVB-induced inflammatory cytokines in human keratinocytes.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29180440","citation_count":26,"is_preprint":false},{"pmid":"15714128","id":"PMC_15714128","title":"Alterations of the tissue inhibitor of metalloproteinase-3 (TIMP3) gene in pancreatic adenocarcinomas.","date":"2005","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/15714128","citation_count":26,"is_preprint":false},{"pmid":"30584323","id":"PMC_30584323","title":"miR-222-3p promotes osteosarcoma cell migration and invasion through targeting TIMP3.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30584323","citation_count":25,"is_preprint":false},{"pmid":"29134286","id":"PMC_29134286","title":"Proteomic and metabolomic characterization of streptozotocin-induced diabetic nephropathy in TIMP3-deficient mice.","date":"2017","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/29134286","citation_count":25,"is_preprint":false},{"pmid":"30415251","id":"PMC_30415251","title":"MicroRNA-323a-3p Promotes Pressure Overload-Induced Cardiac Fibrosis by Targeting TIMP3.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30415251","citation_count":25,"is_preprint":false},{"pmid":"27077469","id":"PMC_27077469","title":"MiR-221 Exacerbate Cell Proliferation and Invasion by Targeting TIMP3 in Papillary Thyroid Carcinoma.","date":"2017","source":"American journal of therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27077469","citation_count":24,"is_preprint":false},{"pmid":"31921636","id":"PMC_31921636","title":"A Strong Decrease in TIMP3 Expression Mediated by the Presence of miR-17 and 20a Enables Extracellular Matrix Remodeling in the NSCLC Lesion Surroundings.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31921636","citation_count":24,"is_preprint":false},{"pmid":"30279425","id":"PMC_30279425","title":"Increased TIMP-3 expression alters the cellular secretome through dual inhibition of the metalloprotease ADAM10 and ligand-binding of the LRP-1 receptor.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30279425","citation_count":24,"is_preprint":false},{"pmid":"22848309","id":"PMC_22848309","title":"Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance.","date":"2011","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/22848309","citation_count":23,"is_preprint":false},{"pmid":"29373036","id":"PMC_29373036","title":"TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.","date":"2018","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29373036","citation_count":23,"is_preprint":false},{"pmid":"23598435","id":"PMC_23598435","title":"Ultrasound-targeted HSVtk and Timp3 gene delivery for synergistically enhanced antitumor effects in hepatoma.","date":"2013","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23598435","citation_count":23,"is_preprint":false},{"pmid":"34155343","id":"PMC_34155343","title":"Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34155343","citation_count":23,"is_preprint":false},{"pmid":"27476612","id":"PMC_27476612","title":"Dissecting the interaction between tissue inhibitor of metalloproteinases-3 (TIMP-3) and low density lipoprotein receptor-related protein-1 (LRP-1): Development of a \"TRAP\" to increase levels of TIMP-3 in the tissue.","date":"2016","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/27476612","citation_count":23,"is_preprint":false},{"pmid":"18295466","id":"PMC_18295466","title":"Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy.","date":"2008","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/18295466","citation_count":22,"is_preprint":false},{"pmid":"37783408","id":"PMC_37783408","title":"Asiaticoside-nitric oxide promoting diabetic wound healing through the miRNA-21-5p/TGF-β1/SMAD7/TIMP3 signaling pathway.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37783408","citation_count":22,"is_preprint":false},{"pmid":"22053204","id":"PMC_22053204","title":"TIMP3 regulates mammary epithelial apoptosis with immune cell recruitment through differential TNF dependence.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22053204","citation_count":22,"is_preprint":false},{"pmid":"33560588","id":"PMC_33560588","title":"CircCSNK1G3 up-regulates miR-181b to promote growth and metastasis via TIMP3-mediated epithelial to mesenchymal transitions in renal cell carcinoma.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33560588","citation_count":21,"is_preprint":false},{"pmid":"29775626","id":"PMC_29775626","title":"MicroRNA-21 up-regulates metalloprotease by down-regulating TIMP3 during cumulus cell-oocyte complex in vitro maturation.","date":"2018","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29775626","citation_count":21,"is_preprint":false},{"pmid":"27314542","id":"PMC_27314542","title":"Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature.","date":"2016","source":"Journal of neurosurgery. Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/27314542","citation_count":21,"is_preprint":false},{"pmid":"24048576","id":"PMC_24048576","title":"Ovarian expression, localization, and function of tissue inhibitor of metalloproteinase 3 (TIMP3) during the periovulatory period of the human menstrual cycle.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/24048576","citation_count":20,"is_preprint":false},{"pmid":"29467412","id":"PMC_29467412","title":"IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29467412","citation_count":20,"is_preprint":false},{"pmid":"12757930","id":"PMC_12757930","title":"Expression of mutant and wild-type TIMP3 in primary gingival fibroblasts from Sorsby's fundus dystrophy patients.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12757930","citation_count":19,"is_preprint":false},{"pmid":"32107793","id":"PMC_32107793","title":"Loss of TIMP3 expression induces inflammation, matrix degradation, and vascular ingrowth in nucleus pulposus: A new mechanism of intervertebral disc degeneration.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32107793","citation_count":19,"is_preprint":false},{"pmid":"23023527","id":"PMC_23023527","title":"A novel mutation at the N-terminal domain of the TIMP3 gene in Sorsby fundus dystrophy.","date":"2013","source":"Retina (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/23023527","citation_count":18,"is_preprint":false},{"pmid":"17897911","id":"PMC_17897911","title":"TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721.","date":"2007","source":"Hepatobiliary & pancreatic diseases international : HBPD INT","url":"https://pubmed.ncbi.nlm.nih.gov/17897911","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53855,"output_tokens":7755,"usd":0.138945},"stage2":{"model":"claude-opus-4-6","input_tokens":11557,"output_tokens":4274,"usd":0.246952},"total_usd":0.385897,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"The N-terminal inhibitory domain of TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5), with Ki values in the subnanomolar range, establishing TIMP-3 as the first endogenous regulator of aggrecanases.\",\n      \"method\": \"In vitro enzymatic inhibition assay with recombinant N-terminal TIMP-3 domain expressed from bacterial inclusion bodies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro kinetic inhibition assay with defined Ki values, rigorous biochemical characterization\",\n      \"pmids\": [\"11278243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TIMP-3 (but not TIMP-2 or TIMP-4) inhibits ADAM-10 with an apparent inhibition constant of ~0.9 nM, and is the only TIMP able to inhibit both ADAM-10 and TACE (ADAM-17).\",\n      \"method\": \"Quenched fluorescent substrate assay and myelin basic protein degradation assay using recombinant ADAM-10 catalytic domain\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic inhibition with quantified Ki, multiple substrate assays\",\n      \"pmids\": [\"10818225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Under basal conditions, TACE (ADAM17) exists predominantly as cell-surface dimers that associate efficiently with TIMP3 to suppress TACE activity; activation of ERK or p38 MAPK shifts the equilibrium toward TACE monomers, reducing TIMP3 association and increasing TACE-mediated proteolysis.\",\n      \"method\": \"Cell-surface dimerization assays, co-immunoprecipitation of TACE with TIMP3, MAPK pathway manipulation, TGF-α shedding readout\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, multiple pathway manipulations, defined mechanistic model with functional readout\",\n      \"pmids\": [\"22550340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TIMP3 deficiency leads to unchecked TACE activity, increased soluble TNF-α, and promotes diabetes and vascular inflammation; pharmacological TACE inhibition reverses these phenotypes, placing TIMP3 upstream of TACE/TNF-α signaling in metabolic disease.\",\n      \"method\": \"Genetic epistasis in Insr+/- and Insr+/-Timp3+/- double heterozygous mice; TACE activity assays; pharmacological TACE inhibition rescue experiments\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double mutant mice, pharmacological rescue, TACE activity measurements\",\n      \"pmids\": [\"16294222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TIMP-3 deficiency in mice triggers spontaneous dilated cardiomyopathy with elevated MMP-9 activity and TNF-α activation, demonstrating that TIMP-3 is required to maintain myocardial matrix homeostasis and suppress proinflammatory remodeling.\",\n      \"method\": \"Targeted Timp3-knockout mice evaluated longitudinally; gelatinase bioassay for MMP activity; echocardiographic and histological analysis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO model with defined phenotypic readout, MMP activity assays, replicated across aging time points\",\n      \"pmids\": [\"15262835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TIMP3 deficiency accelerates renal tubulointerstitial fibrosis after ureteral obstruction via elevated TACE activity, increased soluble TNF-α, and enhanced MMP-2 activation; additional deletion of TNF-α markedly reduces inflammation and fibrosis, placing TIMP3 upstream of TACE/TNF-α and MMP axes in kidney injury.\",\n      \"method\": \"TIMP3-/- mice and TIMP3-/-/TNFα-/- double-KO mice with unilateral ureteral obstruction; TACE activity assays; gelatin zymography; MMP inhibitor treatment\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic double-KO epistasis, pharmacological inhibition, multiple enzymatic assays\",\n      \"pmids\": [\"19406980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TIMP-3 inhibits ADAM-10 and ADAM-17-mediated alpha-secretase cleavage of APP and ApoER2, decreases their surface levels, and thereby increases beta-secretase cleavage and Aβ production; TIMP-3 protein levels are elevated in Alzheimer's disease brain.\",\n      \"method\": \"Cell-based alpha-secretase/beta-secretase cleavage assays in neuroblastoma and COS7 cells; surface protein measurement; Aβ ELISA; brain tissue immunoblot\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-based functional assays with multiple readouts, in vivo confirmation in transgenic mice and human AD tissue\",\n      \"pmids\": [\"17913923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP3 induces apoptosis in endothelial cells expressing VEGFR2 (KDR) through a caspase-independent mechanism involving inhibition of FAK tyrosine phosphorylation and disruption of β3 integrin/FAK/paxillin incorporation into focal adhesion contacts.\",\n      \"method\": \"Apoptosis assays in PAE/KDR vs PAE/β-R cells; caspase inhibitor experiments; FAK phosphorylation immunoblot; focal adhesion complex co-immunoprecipitation\",\n      \"journal\": \"Apoptosis : an international journal on programmed cell death\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts and mechanistic pathway dissection, single lab\",\n      \"pmids\": [\"25558000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TIMP3 acts through inhibition of the metalloprotease ADAM17 and its substrate HB-EGF to regulate cerebral arterial tone; in CADASIL mice with elevated TIMP3, exogenous ADAM17 or HB-EGF restores cerebral blood flow responses, and upregulated voltage-dependent potassium (KV) channel number in arterial myocytes is identified as a downstream effector.\",\n      \"method\": \"CADASIL mouse model; pharmacological and genetic manipulation of ADAM17/HB-EGF; cerebral blood flow measurements; patch-clamp electrophysiology of cerebral arterial myocytes\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological epistasis, electrophysiology, multiple orthogonal methods in vivo and ex vivo\",\n      \"pmids\": [\"27476853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Elevated TIMP3 in CADASIL mice impairs functional hyperemia and cerebrovascular reactivity; haploinsufficiency of Timp3 rescues these CBF deficits downstream of Notch3ECD deposition, demonstrating TIMP3 accumulation as a causal contributor to cerebrovascular dysfunction.\",\n      \"method\": \"TgNotch3R169C mice crossed with Timp3 haploinsufficient mice; CBF measurements; myogenic tone assays; TgBAC-TIMP3 overexpression mouse\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue in preclinical model, multiple functional vascular assays, TIMP3 overexpression model confirms phenotype\",\n      \"pmids\": [\"26648042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Pericyte-derived TIMP3 stabilizes capillary tube networks and inhibits ADAMTS1-mediated metalloprotease activity in endothelial cells; Timp3-/- mice show spontaneous microvascular rarefaction and exaggerated fibrosis after kidney injury.\",\n      \"method\": \"3D capillary tube network assays with pericytes vs myofibroblasts; Timp3-/- mouse renal injury model; ADAMTS1/TIMP3 expression profiling\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro reconstitution of vascular stabilization, KO mouse with defined phenotype, functional metalloprotease measurements\",\n      \"pmids\": [\"22383695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Pericyte ALK5 (TGF-β receptor) signaling upregulates TIMP3 expression; ALK5-deficient brain pericytes downregulate TIMP3, causing enhanced perivascular MMP activity, endothelial hyperproliferation, and germinal matrix hemorrhage; exogenous TIMP3 administration rescues endothelial morphogenesis.\",\n      \"method\": \"Conditional pericyte Alk5 knockout mice; immunofluorescence; gelatin zymography; TIMP3 rescue administration in vivo\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined cellular phenotype, pharmacological rescue with TIMP3 protein, multiple orthogonal assays\",\n      \"pmids\": [\"29456135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The N-terminal domains of TIMP-1 and TIMP-3 alone are insufficient to inhibit ADAM10; full-length TIMP-3 is required, indicating that regions beyond the N-terminal inhibitory domain contribute to ADAM10 inhibition, unlike the mechanism for MMP and ADAM17 inhibition.\",\n      \"method\": \"In vitro inhibition assays comparing N-terminal domain fragments vs full-length TIMP-1 and TIMP-3 against ADAM10, ADAM17, and MMPs\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro inhibition assays with defined domain constructs\",\n      \"pmids\": [\"18215140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TIMP-3 protein is uniquely deposited in the extracellular matrix of Bruch's membrane in the retina/choroid and is not secreted into culture medium, unlike TIMP-1 and TIMP-2, explaining why TIMP-3 mutations cause retinal-specific pathology (Sorsby's fundus dystrophy).\",\n      \"method\": \"RT-PCR, Northern analysis, Western immunoblot, immunohistochemistry of human retina/choroid and cultured RPE cells and pericytes\",\n      \"journal\": \"Current eye research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular/extracellular localization by multiple orthogonal methods with functional implication\",\n      \"pmids\": [\"9068940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Loss of TIMP3 in diabetic mice causes increased ADAM17 activity and elevated STAT1, which represses FoxO1 transcription; re-expression of TIMP3 in Timp3-/- mesangial cells rescues FoxO1 and its autophagy targets while decreasing STAT1, establishing a TIMP3→ADAM17→STAT1→FoxO1 pathway in diabetic nephropathy.\",\n      \"method\": \"Diabetic Timp3-/- mice; microarray; re-expression experiments in mesangial cells; STAT1 siRNA rescue; kidney biopsies from diabetic patients\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO mouse, cell-based rescue, siRNA epistasis, human tissue validation\",\n      \"pmids\": [\"23401241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TIMP3 inhibits TIMP3 internalization via LRP-1 interaction; TIMP3 extracellular levels are regulated by endocytosis through LRP-1 cluster II; a soluble minireceptor (T3TRAP) that blocks TIMP3 binding to LRP-1 selectively increases extracellular TIMP3 and inhibits ADAM10-mediated shedding of multiple cell-surface proteins.\",\n      \"method\": \"Soluble LRP-1 minireceptor binding assays, biochemical TIMP-3/LRP-1 interaction assays, mass spectrometry-based secretome analysis\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical binding assays with defined domain mapping, MS secretome validation, multiple methods\",\n      \"pmids\": [\"27476612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Increased TIMP-3 expression inhibits ADAM10-mediated shedding of multiple cell-surface proteins and simultaneously increases extracellular levels of soluble proteins (TIMP-1, MIF, SPARC) by competing with them for LRP-1-mediated endocytosis.\",\n      \"method\": \"Unbiased mass spectrometry secretome analysis in TIMP-3-overexpressing HEK293 cells; LRP-1 inactivation comparison\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — unbiased MS proteomics with genetic controls, dual mechanistic findings (ADAM10 inhibition + LRP-1 competition)\",\n      \"pmids\": [\"30279425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TIMP3, but not TIMP2, inhibits pro-MMP2 activation in kidney; TIMP3 deficiency selectively activates TACE, caspase-3, and MAPK pathways in obstructed kidney while TIMP2 deficiency reduces MMP2 activation, demonstrating divergent and contrasting roles in renal injury.\",\n      \"method\": \"TIMP2-/- and TIMP3-/- mice with unilateral ureteral obstruction; gelatin zymography; TACE activity assays; caspase-3 assays\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comparative KO mouse models with multiple enzymatic assays, defined mechanistic divergence\",\n      \"pmids\": [\"23760282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TIMP3 deficiency accelerates mammary gland involution through TNF dysregulation, earlier caspase-3 activation, and mitochondrial apoptosis; TNF deficiency abrogates caspase-3 activation but increases macrophage/T-cell infiltration, demonstrating that TIMP3 differentially controls apoptosis (via TNF) and inflammatory cell influx through distinct mechanisms.\",\n      \"method\": \"Timp3-/- and Timp3-/-/Tnf-/- double-KO mice during mammary involution; caspase assays; histology; flow cytometry\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic double-KO epistasis with multiple mechanistic readouts\",\n      \"pmids\": [\"22053204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Stromal (hepatocyte-derived) TIMP3 regulates basal hepatic lymphocyte populations; TIMP3 deficiency leads to spontaneous accumulation and activation of hepatic CD4+, CD8+, and NKT cells and exacerbated Th1 cytokine response dependent on TNF signaling during Con A-induced autoimmune hepatitis. Bone marrow chimeras confirmed the stromal rather than hematopoietic source of protective TIMP3.\",\n      \"method\": \"Timp3-/- mice; bone marrow chimeras; Con A hepatitis model; flow cytometry; cytokine measurements\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bone marrow chimera epistasis, KO model, multiple immune cell readouts\",\n      \"pmids\": [\"22323541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TIMP3 and TIMP2 play differential roles in cardiac hypertrophy and fibrosis: TIMP3 deficiency causes excess fibrosis (via MMP-independent post-translational stabilization of collagen by osteopontin and SPARC), while TIMP2 deficiency causes hypertrophy; both independently cause diastolic dysfunction.\",\n      \"method\": \"TIMP2-/- and TIMP3-/- mice with angiotensin II infusion; echocardiography; co-culture assays; Western blot for matricellular proteins; collagen crosslinking analysis\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comparative KO models, in vitro co-culture mechanistic studies, multiple orthogonal assays\",\n      \"pmids\": [\"24692173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human TIMP-3 gene is a TATA-less, 5-exon gene mapped to chromosome 22q13.1; its promoter contains multiple Sp1 sites sufficient for basal expression, while the region between -463 and -112 bp confers serum inducibility and cell-cycle regulation.\",\n      \"method\": \"Genomic cloning, somatic cell hybrid mapping, promoter-reporter deletion analysis in cell cycle studies\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural and functional promoter analysis with deletion mapping\",\n      \"pmids\": [\"7487894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The SFD mutation S156C in TIMP3 does not impair MMP2 inhibitory activity but causes the protein to form dimers and accumulate in the ECM; this accumulation is not due to altered turnover rate and does not affect MMP2 or MMP9 levels or activation in patient-derived fibroblasts.\",\n      \"method\": \"Immortalized fibroblast lines from Timp3-/- and Timp3S156C/S156C mice; gelatin zymography; ECM immunoblot; turnover assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-based biochemical assays in genetically defined fibroblast lines, single lab\",\n      \"pmids\": [\"12942551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The SFD-associated S156C mutation in TIMP3 does not impair inhibitory activity against TACE, ADAMTS4/5, or aggrecan-cleaving MMPs, nor its anti-angiogenic properties or VEGF/VEGFR2 blocking activity, suggesting SFD pathogenesis involves loss of a distinct non-protease-inhibitory function rather than imbalanced protease activity.\",\n      \"method\": \"Timp3S156C knock-in mice; TACE, ADAMTS4/5, MMP activity assays; fibrin bead angiogenesis assay; VEGF-VEGFR2 binding assay with recombinant proteins\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple in vitro enzymatic assays and functional rescue with recombinant proteins in genetically defined mouse model\",\n      \"pmids\": [\"18295466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of TIMP3 in ApoE-/- mice increases atherosclerosis with greater macrophage infiltration, elevated MCP-1, and polarization of macrophages toward an inflammatory M1/Gr1+ phenotype, demonstrating a role for TIMP3 in restraining macrophage inflammatory polarization during atherogenesis.\",\n      \"method\": \"ApoE-/-Timp3-/- double-KO mice; en face aorta analysis; flow cytometry of macrophage subsets; serum MCP-1 measurement\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic double-KO model with multiple mechanistic readouts, macrophage phenotyping\",\n      \"pmids\": [\"24943223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hepatocyte-specific TIMP3 overexpression improves glucose metabolism, hepatic fatty acid oxidation, and cholesterol homeostasis during high-fat diet; hepatocyte-specific Adam17 knockout (A17LKO), but not myeloid-specific Adam17 deletion, similarly reduces hepatic steatosis, establishing TIMP3 acts through hepatocyte ADAM17 inhibition to limit NAFLD and hepatocarcinogenesis.\",\n      \"method\": \"AlbT3 (hepatocyte TIMP3 overexpression) and A17LKO/A17MKO (cell-type-specific Adam17 KO) mice on HFD; metabolic assays; diethylnitrosamine tumor model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic epistasis (overexpression + conditional KO), multiple metabolic readouts\",\n      \"pmids\": [\"28751722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TIMP3 expression is regulated by a circadian CLOCK-dependent mechanism in human keratinocytes; CLOCK knockdown reduces TIMP3 expression and inversely increases MMP-1, TNF-α, CXCL1, and IL-8 via C/EBPα; UVB exposure suppresses CLOCK and TIMP3, and TIMP3 knockdown or overexpression modulates UVB-induced TNF-α secretion.\",\n      \"method\": \"CLOCK siRNA knockdown; TIMP3 overexpression/knockdown in keratinocytes; ELISA for secreted cytokines; promoter analysis\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic manipulations with functional readouts, single lab\",\n      \"pmids\": [\"29180440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Human cytomegalovirus (CMV) infection downregulates TIMP3 expression through upregulated cellular and CMV-encoded microRNAs, causing increased ADAM17 and MMP14 activity and enhanced shedding of the NKG2D ligand MICA to evade NK cell recognition.\",\n      \"method\": \"CMV infection of cells; miRNA expression analysis; metalloprotease activity assays; MICA shedding ELISA; soluble MICA detection in patient serum\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-based mechanistic dissection with functional immune readout, human serum validation\",\n      \"pmids\": [\"24973455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KDM1A (histone demethylase) represses TIMP3 transcription by removing H3K4me2 at the TIMP3 promoter; KDM1A overexpression promotes NSCLC cell invasion and migration, which is rescued by TIMP3 overexpression; TIMP3 in turn suppresses MMP2 expression and JNK phosphorylation.\",\n      \"method\": \"KDM1A KD/OE in NSCLC cells; ChIP for H3K4me2 at TIMP3 promoter; invasion/migration assays; TIMP3 rescue experiments; pharmacological inhibition\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP mechanistic validation, genetic rescue experiments, single lab\",\n      \"pmids\": [\"27058897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TIMP3 promotes apoptotic cell death in small cell lung cancer cells that lack functional caspase-8 (adenovirally delivered TIMP3), indicating TIMP3 can induce apoptosis through a caspase-8-independent pathway in suspension-growing tumor cells.\",\n      \"method\": \"Adenoviral TIMP3 delivery to suspension-growing SCLC cell lines SW2 and N417; apoptosis assays; caspase-8 functional analysis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function/gain-of-function with mechanistic pathway exclusion, single lab\",\n      \"pmids\": [\"20473894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDAC9 promotes trophoblast cell migration and invasion by repressing TIMP3 through promoter histone hypoacetylation; HDAC9 knockdown increases histone acetylation at the TIMP3 promoter (by ChIP-qPCR) and upregulates TIMP3, inhibiting trophoblast invasion in preeclampsia.\",\n      \"method\": \"HDAC9 siRNA knockdown; ChIP-qPCR for TIMP3 promoter histone acetylation; transwell migration/invasion assays\",\n      \"journal\": \"American journal of hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-qPCR mechanistic validation, functional rescue, single lab\",\n      \"pmids\": [\"30715128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MSI1 (Musashi1) RNA-binding protein directly suppresses TIMP3 expression, reducing TIMP3-mediated inhibition of MMP9, thereby promoting invadopodia formation and ECM degradation in breast cancer metastasis; TIMP3 and MSI1 expression are inversely correlated in clinical specimens.\",\n      \"method\": \"MSI1 KD/OE in mammary cancer cells; invadopodia formation assays; MMP9 activity; TIMP3 rescue; clinical tissue correlation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic cascade established by KD/rescue experiments with functional readout, clinical validation\",\n      \"pmids\": [\"34155343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In periovulatory granulosa cells, hCG induces biphasic TIMP3 expression via PKA, PKC, MAPK, progesterone receptor, and EGF receptor pathways; siRNA knockdown of Timp3 reduces hCG-induced progesterone levels by ~20%, indicating TIMP3 regulates steroidogenesis during ovulation.\",\n      \"method\": \"Rat granulosa cell isolation; pharmacological pathway inhibitors; Timp3-specific siRNA; progesterone measurement; microarray analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA functional knockdown with defined steroidogenic readout, multiple pathway inhibitors\",\n      \"pmids\": [\"19389837\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TIMP3 is an ECM-bound broad-spectrum metalloproteinase inhibitor that blocks MMPs, aggrecanases (ADAMTS4/5), ADAM10, and ADAM17/TACE with sub-nanomolar potency; its extracellular bioavailability is regulated by LRP-1-mediated endocytosis; by restraining TACE activity it controls TNF-α shedding, EGFR ligand release, and NKG2D ligand shedding; it additionally blocks VEGFR2 signaling to suppress angiogenesis and regulates cerebral arterial tone via the ADAM17/HB-EGF/KV channel axis; loss of TIMP3 causes spontaneous cardiomyopathy, renal fibrosis, and vascular dysfunction through unchecked MMP and TACE activity, establishing it as a critical extracellular brake on protease-driven tissue remodeling and inflammation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TIMP3 is an extracellular matrix-sequestered metalloproteinase inhibitor that serves as a master brake on protease-driven tissue remodeling, inflammation, and vascular homeostasis. It inhibits MMPs, aggrecanases (ADAMTS4/5), ADAM10, and ADAM17/TACE with sub-nanomolar potency, using its N-terminal domain for MMP and aggrecanase inhibition but requiring its full-length structure for ADAM10 blockade [PMID:11278243, PMID:10818225, PMID:18215140]. By suppressing TACE activity, TIMP3 controls TNF-α shedding, EGFR ligand release, NKG2D ligand shedding, and downstream STAT1/FoxO1 signaling; its extracellular bioavailability is regulated by LRP-1-mediated endocytosis, and its loss causes spontaneous dilated cardiomyopathy, renal fibrosis, accelerated atherosclerosis, and metabolic disease through unchecked TACE and MMP activity [PMID:15262835, PMID:16294222, PMID:19406980, PMID:27476612, PMID:23401241, PMID:24943223]. Mutations in TIMP3 (e.g., S156C) cause Sorsby's fundus dystrophy, linked to its unique ECM deposition in Bruch's membrane, though the S156C mutation preserves protease-inhibitory function and instead causes abnormal dimerization and ECM accumulation [PMID:9068940, PMID:12942551, PMID:18295466].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing the genomic architecture of TIMP3 — a TATA-less gene on chromosome 22q13.1 with Sp1-dependent basal transcription and serum-inducible upstream elements — provided the foundation for understanding its transcriptional regulation.\",\n      \"evidence\": \"Genomic cloning, somatic cell hybrid mapping, and promoter-reporter deletion analysis in cell cycle studies\",\n      \"pmids\": [\"7487894\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factor binding to the serum-responsive element not identified\", \"No chromatin-level regulation addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating that TIMP3 protein is uniquely sequestered in the ECM (Bruch's membrane) rather than being secreted into medium explained why TIMP3 mutations cause the retinal-specific Sorsby's fundus dystrophy, unlike other TIMPs.\",\n      \"evidence\": \"RT-PCR, Northern, Western blot, and immunohistochemistry of human retina/choroid and cultured RPE cells\",\n      \"pmids\": [\"9068940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinants of ECM binding not identified\", \"Whether ECM sequestration differs across tissue types not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identifying TIMP3 as the sole TIMP capable of inhibiting both ADAM10 and TACE (ADAM17) at sub-nanomolar potency expanded its functional scope beyond MMP inhibition to regulation of ADAMs-mediated ectodomain shedding.\",\n      \"evidence\": \"Quenched fluorescent substrate assay and myelin basic protein degradation assay with recombinant ADAM10 catalytic domain\",\n      \"pmids\": [\"10818225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for TIMP3 selectivity toward ADAMs not determined\", \"In vivo relevance of ADAM10 inhibition not yet shown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showing that the N-terminal domain of TIMP3 potently inhibits aggrecanases ADAMTS4 and ADAMTS5 (Ki < 1 nM) established TIMP3 as the first known endogenous regulator of cartilage-degrading aggrecanases.\",\n      \"evidence\": \"In vitro enzymatic inhibition assay with recombinant N-terminal TIMP3 domain\",\n      \"pmids\": [\"11278243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo cartilage protection by endogenous TIMP3 not demonstrated\", \"Aggrecanase inhibition mechanism at the structural level not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Analyzing the Sorsby's fundus dystrophy S156C mutation revealed it causes TIMP3 dimerization and ECM accumulation without impairing MMP2 inhibition, redirecting pathogenic models away from simple loss of protease inhibitory function.\",\n      \"evidence\": \"Immortalized fibroblast lines from Timp3S156C/S156C mice; gelatin zymography; ECM immunoblot; turnover assays\",\n      \"pmids\": [\"12942551\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab study\", \"Downstream consequence of ECM accumulation on retinal physiology not tested\", \"Whether dimerization affects ADAM inhibition not assessed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Timp3-knockout mice developing spontaneous dilated cardiomyopathy with elevated MMP-9 and TNF-α provided the first in vivo proof that TIMP3 is indispensable for maintaining myocardial matrix homeostasis.\",\n      \"evidence\": \"Targeted Timp3-KO mice evaluated longitudinally; gelatinase bioassay; echocardiography and histology\",\n      \"pmids\": [\"15262835\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cardiomyopathy is MMP- or TACE-dependent not dissected\", \"Cell-type-specific contributions within heart not determined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic epistasis placing TIMP3 upstream of TACE/TNF-α in metabolic disease — with pharmacological TACE inhibition rescuing vascular inflammation in TIMP3-deficient mice — established the TIMP3→TACE→TNF-α axis as a central inflammatory circuit.\",\n      \"evidence\": \"Insr+/-Timp3+/- double heterozygous mice; TACE activity assays; pharmacological TACE inhibitor rescue\",\n      \"pmids\": [\"16294222\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of other TACE substrates besides TNF-α not dissected\", \"Human metabolic disease relevance not directly tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Two key advances refined the inhibitory mechanism: full-length TIMP3 was shown to be required for ADAM10 inhibition (unlike for MMPs/ADAM17), and the S156C SFD mutation was found to preserve all tested protease-inhibitory and anti-angiogenic functions, suggesting SFD involves a non-protease-inhibitory mechanism.\",\n      \"evidence\": \"In vitro domain-truncation inhibition assays; Timp3S156C knock-in mice with TACE, ADAMTS, MMP, and VEGFR2-binding assays\",\n      \"pmids\": [\"18215140\", \"18295466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C-terminal structural contacts with ADAM10 not mapped\", \"The non-protease-inhibitory pathogenic mechanism in SFD remains unidentified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Double-KO epistasis (Timp3−/−/TNFα−/−) in renal obstruction proved that TIMP3 restrains kidney fibrosis via dual TACE/TNF-α and MMP-2 axes, with TNF-α deletion rescuing most inflammatory injury.\",\n      \"evidence\": \"TIMP3−/− and TIMP3−/−/TNFα−/− double-KO mice with unilateral ureteral obstruction; TACE activity; gelatin zymography\",\n      \"pmids\": [\"19406980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of TNF-dependent vs MMP-dependent fibrosis not fully quantified\", \"Cell-type-specific source of renal TIMP3 not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"During mammary involution, TIMP3 differentially controls apoptosis (via TNF) and inflammatory cell influx through distinct mechanisms, as shown by double-KO epistasis where TNF deletion abrogated caspase-3 activation but paradoxically increased macrophage/T-cell infiltration.\",\n      \"evidence\": \"Timp3−/− and Timp3−/−/Tnf−/− double-KO mice during mammary involution; caspase assays; flow cytometry\",\n      \"pmids\": [\"22053204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the TNF-independent inflammatory target protease not established\", \"Whether this bifurcation applies in other tissues not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Multiple 2012 studies converged on how TIMP3 integrates into tissue-specific protease control: TACE dimerization governs TIMP3 association at the cell surface, pericyte-derived TIMP3 stabilizes capillaries via ADAMTS1 inhibition, stromal TIMP3 regulates hepatic immune populations, and TIMP3 and TIMP2 have divergent roles in renal injury.\",\n      \"evidence\": \"TACE dimerization/co-IP assays; 3D capillary tube networks with pericytes; bone marrow chimeras in Con A hepatitis; comparative TIMP2−/−/TIMP3−/− kidney models\",\n      \"pmids\": [\"22550340\", \"22383695\", \"22323541\", \"23760282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of TACE dimer–TIMP3 interaction unknown\", \"Whether pericyte TIMP3 acts through the same TACE/TNF axis not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"In diabetic nephropathy, TIMP3 loss activates ADAM17 leading to elevated STAT1 that represses FoxO1 and autophagy; TIMP3 re-expression rescues this cascade, establishing TIMP3→ADAM17→STAT1→FoxO1 as a signaling axis in metabolic kidney disease.\",\n      \"evidence\": \"Diabetic Timp3−/− mice; microarray; mesangial cell re-expression; STAT1 siRNA rescue; human kidney biopsies\",\n      \"pmids\": [\"23401241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which ADAM17 substrate mediates STAT1 activation not identified\", \"Whether this axis operates in non-renal diabetic complications not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"TIMP3's anti-inflammatory role was extended to atherosclerosis (macrophage M1 polarization in ApoE−/−Timp3−/− mice) and cardiac fibrosis (MMP-independent collagen stabilization via osteopontin/SPARC), revealing protease-independent functions.\",\n      \"evidence\": \"ApoE−/−Timp3−/− mice with en face aorta analysis and macrophage flow cytometry; TIMP3−/− mice with AngII infusion and collagen crosslinking analysis\",\n      \"pmids\": [\"24943223\", \"24692173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which TIMP3 deficiency elevates osteopontin/SPARC not resolved\", \"Direct protease target responsible for macrophage polarization not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Three breakthroughs in 2016 clarified TIMP3 bioavailability and vascular function: LRP-1 cluster II mediates TIMP3 endocytosis and a soluble minireceptor (T3TRAP) blocks this to increase extracellular TIMP3; elevated TIMP3 in CADASIL causes cerebrovascular dysfunction via ADAM17/HB-EGF/KV channel axis; and Timp3 haploinsufficiency rescues CADASIL cerebral blood flow deficits.\",\n      \"evidence\": \"Biochemical LRP-1 binding assays and MS secretome; CADASIL mouse pharmacological/genetic rescue with CBF measurement and patch-clamp electrophysiology; TgNotch3R169C × Timp3+/− mice\",\n      \"pmids\": [\"27476612\", \"27476853\", \"26648042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether T3TRAP is effective in vivo not demonstrated\", \"Whether TIMP3 accumulation in CADASIL is the sole pathogenic mediator vs other trapped ECM proteins\", \"Structural basis of LRP-1 cluster II–TIMP3 interaction not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Hepatocyte-specific TIMP3 overexpression phenocopied hepatocyte-specific Adam17 deletion in protecting against NAFLD and hepatocarcinogenesis, confirming the TIMP3–ADAM17 axis operates cell-autonomously in hepatocytes to control lipid metabolism.\",\n      \"evidence\": \"AlbT3 and A17LKO conditional mice on HFD; metabolic assays; diethylnitrosamine tumor model\",\n      \"pmids\": [\"28751722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ADAM17 substrates responsible for hepatic lipid accumulation not identified\", \"Whether myeloid TIMP3 has independent liver-protective roles not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Two studies linked TIMP3 to pericyte TGF-β signaling and to LRP-1-mediated secretome remodeling: pericyte ALK5 drives TIMP3 expression to suppress perivascular MMP activity and prevent germinal matrix hemorrhage, while TIMP3 overexpression competes with other LRP-1 cargo (TIMP-1, MIF, SPARC) for endocytosis.\",\n      \"evidence\": \"Conditional pericyte Alk5-KO mice with TIMP3 rescue; MS secretome in TIMP3-overexpressing HEK293 with LRP-1 inactivation comparison\",\n      \"pmids\": [\"29456135\", \"30279425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TIMP3 competition for LRP-1 is physiologically relevant at endogenous expression levels\", \"Downstream consequences of altered MIF/SPARC clearance not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for TIMP3's selective inhibition of ADAMs versus MMPs; the identity of the non-protease-inhibitory function lost in Sorsby's fundus dystrophy; the cell-type-specific transcriptional and post-transcriptional regulatory network controlling TIMP3 levels in vivo; and the therapeutic potential of modulating TIMP3 bioavailability (e.g., via LRP-1 blockade) in disease.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure of TIMP3 in complex with an ADAM family member\", \"SFD pathogenic mechanism remains undefined despite exclusion of protease-inhibitory loss\", \"In vivo therapeutic efficacy of T3TRAP or similar LRP-1-blocking strategies not tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 12]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [13, 22]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [13, 15, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 4, 5, 10, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 19, 24, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 14, 25]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7, 18, 29]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ADAM17\",\n      \"ADAM10\",\n      \"ADAMTS4\",\n      \"ADAMTS5\",\n      \"LRP1\",\n      \"MMP9\",\n      \"MMP2\",\n      \"KDR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}